Economy Minister Dr Caoimhe Archibald has launched a comprehensive roadmap positioning Northern Ireland to capitalise on engineering biology—a field that fuses biological science with engineering principles to create new medicines, sustainable fuels and advanced materials. Published on 27 April 2026, the report identifies six priority sectors where the region could secure a competitive edge in a global bioeconomy projected to be worth $4 trillion annually by the end of the decade.
The report, Engineering Biology in Northern Ireland: A Strategic Roadmapping Study, represents the first integrated framework for developing the region’s capabilities in this emerging discipline. Commissioned by Matrix, the Northern Ireland Science Industry Panel, and delivered by IfM Engage at the University of Cambridge, the study arrives as the UK government prioritises engineering biology as one of five “critical technologies” essential to national competitiveness.
Six Priority Sectors Identified
The roadmap pinpoints specific sectors where Northern Ireland holds internationally competitive strengths, particularly in diagnostics, precision medicine, agri-food and advanced manufacturing. The six priority areas for development comprise:
- Diagnostics and Biosensors
- Food Security and Resilience
- Large-Scale Capabilities and Industrial Biotechnology
- Circular Bioeconomy
- Agri-Tech Innovation
- One Health (integrating human, animal and environmental health)
Engineering biology applies engineering principles such as the “design, build, test, learn” cycle to biological systems, enabling the creation of organisms or biological systems with novel functions. Applications range from gene therapies and personalised medicines to bio-based polymers, sustainable aviation fuels and climate-resilient crops.
Coordination, Skills and Regulatory Strategy
The report warns that Northern Ireland risks merely adopting solutions developed elsewhere unless it establishes proper coordination mechanisms. Key recommendations include establishing a cross-departmental engineering biology coordination body to develop a proactive regulatory strategy—one that maximises the advantages of the Windsor Framework for medicines and agri-tech products. The roadmap also demands a comprehensive skills and workforce strategy spanning doctoral training through to technician-level apprenticeships, alongside a sustained public engagement programme to communicate practical benefits to the public and policymakers.
Ministerial and Expert Commentary
Minister Archibald emphasised the transformative potential of the sector: “Engineering biology has the potential to transform how we approach healthcare, food production, manufacturing and our environment. From diagnostics and precision medicine to agri-food innovation and the circular bioeconomy, its applications span some of the north’s most important industries. This roadmap gives us the evidence-based foundation to consider how best to act on that potential.”
Professor Sam Turner, Chair of the study, stressed that scientific excellence already exists in Northern Ireland but requires structural support: “Northern Ireland has genuine, internationally competitive strengths in engineering biology, particularly in diagnostics, health and agri-food. What has been missing is not scientific excellence, but coordination, scale-up capability and long-term strategic commitment. This roadmap provides a clear, evidence-based pathway so that Northern Ireland can help shape the future of engineering biology rather than simply adopting the solutions that have been developed elsewhere.”
Professor Helen McCarthy, Chief Scientific and Technology Adviser and Matrix Ex Officio, placed the report in a UK-wide context: “Engineering Biology is a critical technology that will drive future economic growth through innovation. In essence, it fuses biological knowledge with chemical, engineering and manufacturing processes to produce new medicines, agricultural products, sustainable fuels and advanced materials, all of which are underpinned by greener, more energy-efficient systems. This MATRIX report is very timely, in the context of the UK Industrial Strategy, and critically, it not only showcases the key strengths in the NI ecosystem but, more importantly, it highlights what is required to accelerate innovation in this field for maximal impact.”
UK Industrial Strategy Context
The publication aligns with the UK government’s Industrial Strategy, which identifies engineering biology as one of six “frontier industries” alongside artificial intelligence, quantum technologies and semiconductors. The UK government has allocated £196 million for a National Engineering Biology Programme and £184 million for scale-up infrastructure across the UK, though specific allocations for Northern Ireland remain unclear.
Matrix—the industry-led panel advising government on R&D commercialisation—notes that the global bioeconomy could generate $2 to $4 trillion in annual economic impact between 2030 and 2040. However, the UK faces intense competition from the United States and China, which currently lead the field, as well as from EU nations, India and Japan that are rapidly increasing investment.
Funding Gaps and Strategic Uncertainties
While the roadmap provides a strategic framework, several crucial details remain unspecified. The report does not quantify the public investment required to implement its recommendations, nor does it establish concrete timelines for establishing the proposed coordination body. With the UK Industrial Strategy already committing billions to engineering biology infrastructure in England—particularly in the “Golden Triangle” of London, Oxford and Cambridge—questions persist about how Northern Ireland will secure proportional funding to avoid a widening regional innovation gap.
The Windsor Framework offers Northern Ireland unique regulatory advantages, allowing simultaneous access to UK and EU markets for certain products. However, the report does not detail how these arrangements will interact with the UK’s proposed gene editing regulations or whether divergence between UK and EU biotech standards could complicate cross-border trade on the island of Ireland.
Furthermore, while the report calls for a skills strategy, it does not address the immediate shortage of laboratory technicians and bioprocessing engineers currently affecting the UK life sciences sector, nor how Northern Ireland might retain talent when larger clusters in Cambridge and London offer significantly higher salaries.
Implementation Timeline and Outstanding Questions
The Department for the Economy must now respond to the roadmap’s recommendations. Key questions for stakeholders include:
- Will the Executive commit specific funding to establish the proposed cross-departmental coordination body before the end of 2026?
- How will Northern Ireland’s engineering biology strategy align with the UK-wide £380 million investment in the sector announced in the Industrial Strategy?
- Can the region leverage the Windsor Framework to position itself as a bridge for biotech trade between Great Britain and the European Union?
- What safeguards will ensure that public engagement addresses legitimate concerns about genetic modification while promoting innovation?
- How will universities and further education colleges collaborate to deliver the technical apprenticeships the report identifies as critical?
The full report is available via the Matrix website. Industry, academic and public stakeholders will likely scrutinise the Executive’s response to determine whether this roadmap translates into tangible investment or remains an aspirational document amid competing budgetary pressures.